YOLFTbeta
68

Hinova Pharmaceuticals Inc. A

688302 · SHG · Healthcare / Biotechnology

31.90CNY-1.00 (-3.04%)

Price History

Full chart

Market Stats

Previous Close32.90
Open32.75
Day Range31.56 – 33.10
52-Week Range28.68 – 60.00
Volume1.80M
Market Cap3.30B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.34
Dividend Yield0.00%
Beta-0.07
50-Day Avg33.79
200-Day Avg40.87

About

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemical indicators; HP570, an orally administered molecular gel degrader targeting VAV1; and HC-X049, a small molecule project with STAT6 target layout. Hinova Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Chengdu, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Yuanwei Chen Ph.D.
  • Employees262
  • HeadquartersBuilding 1, Rongyao Building, Chengdu, China, 610041, China
  • Websitehttps://www.hinovapharma.com

Leadership

  • Dr. Yuanwei Chen Ph.D.Chairman of the Board & General Manager · b. 1963
  • Ms. Ze Yan ShiFinancial Director · b. 1981
  • Jun HuAccounting Supervisor
  • Tango TangVice President of Marketing
  • Mr. Lei FanSenior Vice President of Pharmaceutical Chemistry · b. 1976
  • Mr. Wu DuSenior Vice President of Pharmaceutical Chemistry · b. 1972
  • Mr. Tong Tao KuangVice President of CMC · b. 1981

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.23M001.65M0366.84K20.47M
Growth (%)--100.00%---100.00%-+5480.11%
Cost of Revenue268.82K--766.47K-335.92K282.82K
Gross Profit3.96M00884.36K030.92K20.19M
Gross Margin93.64%--53.57%-8.43%98.62%
Operating Expense115.49M481.49M326.84M338.59M330.64M223.03M177.54M
Operating Income-111.54M-481.49M-326.84M-337.70M-330.64M-223.00M-157.36M
Operating Margin-2638.92%---20456.66%--60789.31%-768.72%
EBITDA-110.94M-489.18M-302.64M-292.12M-286.23M-192.99M-129.61M
EBITDA Margin-2624.81%---17695.40%--52608.76%-633.17%
Net Income-111.70M-489.85M-306.18M-301.51M-294.16M-199.50M-137.25M
Net Income Margin-2642.93%---18264.52%--54382.77%-670.51%
R&D116.10M428.93M264.93M251.37M248.27M174.03M112.71M
R&D as % of Total Revenue2746.80%--15226.80%-47441.25%550.60%
Interest Expense392.60K361.77K2.56M3.92M1.49M526.61K354.11K
Interest Expense % of Total Revenue9.29%--237.73%-143.55%1.73%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets44.72M1.19B982.35M1.74B1.49B1.36B1.31B
Total Liabilities80.50M202.33M193.59M149.68M124.47M169.33M246.19M
Total Equity-36.17M986.15M788.76M1.59B1.37B1.19B1.06B
Cash19.73M1.14B901.22M1.20B813.23M633.44M438.18M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-81.43M-243.66M-227.82M-314.92M-255.51M-187.08M-108.88M
Capital Expenditure1.13M2.50M19.77M69.21M99.18M89.55M82.89M
Free Cash Flow-82.56M-246.16M-247.60M-384.13M-354.68M-276.63M-191.76M
Dividends Paid392.60K361.17K2.56M3.92M904.00K-1.24M
FCF to OCF101.39%101.03%108.68%121.98%138.82%147.87%176.13%
Dividend Paid to FCF-0.48%-0.15%-1.03%-1.02%-0.25%--0.65%

Earnings

Report DateAug 30, 2022Oct 27, 2022Feb 27, 2023Apr 27, 2023
EPS Estimate----
EPS Actual-0.62-0.75-0.80-0.76
Surprise----
TimingAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap3.30B
Enterprise Value2.65B
Trailing P/E0.00
Forward P/E0.00
Price / Sales53.01
Price / Book3.31
EPS-1.34
Book Value10.18
Revenue (TTM)62.27M
Gross Profit (TTM)60.59M
EBITDA-163.99M
Profit Margin-211.36%
Operating Margin-122.06%
Return on Equity-12.27%
Return on Assets-8.00%
Shares Outstanding99.02M
Shares Float71.83M
Beta-0.07
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%